Our previous works have found that MeCP2 promotes HEPG2 cell proliferation in human hepatocellular carcinoma by activating ERK1/2 and inhibiting p38 activity [13] and facilitates breast cancer growth by promoting ubiquitination-mediated P53 degradation by binding to the RPL5/RPL11 promoter regions to suppress RPL5/RPL11 transcription [14]. This evidence concerns the gene RPL11 and breast cancer.